Influenza Clinical Trial
Official title:
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adults 18 Years of Age and Older
| Verified date | October 2023 |
| Source | Sanofi |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin compared to an active control quadrivalent recombinant influenza vaccine (RIV4) in adults 18 years of age and older. Study details include: Study Duration: approximately 6 months Treatment Duration: 1 injection of mRNA vaccine encoding influenza hemagglutinin encoding influenza hemagglutinin or control. Visit Frequency: Screening visit, Day 01, Day 02, Day 03, Day 09, Day 29, Day 91, Day 181
| Status | Completed |
| Enrollment | 388 |
| Est. completion date | February 17, 2023 |
| Est. primary completion date | February 17, 2023 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Having given written informed consent prior to undertaking any study-related procedure. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: - Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
| Country | Name | City | State |
|---|---|---|---|
| United States | AES Austin Site Number : 8400021 | Austin | Texas |
| United States | Benchmark Research - Austin Site Number : 8400006 | Austin | Texas |
| United States | Elligo Health Research, Inc. Site Number : 8400035 | Austin | Texas |
| United States | AMR Coral Gables/Miami, Formerly Clinical Research of South Florida, an AMR company (Clinic) Site Number : 8400004 | Coral Gables | Florida |
| United States | AMR El Dorado Site Number : 8400009 | El Dorado | Kansas |
| United States | Research Centers of America Site Number : 8400003 | Hollywood | Florida |
| United States | AMR Knoxville Site Number : 8400027 | Knoxville | Tennessee |
| United States | AMR Lexington Site Number : 8400014 | Lexington | Kentucky |
| United States | Benchmark Research Site Number : 8400010 | Metairie | Louisiana |
| United States | AMR - Newton Site Number : 8400005 | Newton | Kansas |
| United States | Coastal Carolina Research Center - N Charleston Site Number : 8400008 | North Charleston | South Carolina |
| United States | Quality Clinical Research Site Number : 8400018 | Omaha | Nebraska |
| United States | Velocity Clinical Research, Omaha Site Number : 8400007 | Omaha | Nebraska |
| United States | AES Peoria Site Number : 8400017 | Peoria | Illinois |
| United States | Peninsula Research Associates Site Number : 8400013 | Rolling Hills Estates | California |
| United States | Clinical Trials of Texas, Inc. Site Number : 8400012 | San Antonio | Texas |
| United States | Optimal Research Site Number : 8400026 | San Diego | California |
| United States | Meridian Clinical Research, LLC Site Number : 8400016 | Savannah | Georgia |
| United States | Velocity Clinical Research Vestal Site Number : 8400033 | Vestal | New York |
| United States | AMR Wichita West Site Number : 8400030 | Wichita | Kansas |
| Lead Sponsor | Collaborator |
|---|---|
| Sanofi Pasteur, a Sanofi Company |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Presence of any unsolicited systemic adverse events (AEs) reported in the 30 minutes after injection | Number of participants with unsolicited systemic immediate adverse events (AEs) | Within 30 minutes after injection | |
| Primary | Presence of solicited injection site reactions (ie, pre listed in the participant's diary card [DC] and in the electronic case report form [eCRF]) occurring up to 7 days after injection | Number of participants with solicited injection site reactions | Up to 7 days after injection | |
| Primary | Presence of solicited systemic reactions (ie, pre-listed in the participant's DC and in the eCRF) occurring up to 7 days after injection | Number of participants with solicited systemic reactions | Up to 7 days after injection | |
| Primary | Presence of unsolicited AEs reported up to 28 days after injection | Number of participants with unsolicited AEs | Up to 28 days after injection | |
| Primary | Presence of medically attended AEs (MAAEs) reported up to 28 days after injection | Number of participants with medically attended adverse events (MAAE)s | Up to 28 days after injection | |
| Primary | Presence of serious adverse events (SAEs) and adverse events of special interest (AESIs) throughout the study | Number of participants with serious adverse events (SAEs) | From baseline up to 6 months | |
| Primary | Presence of out-of-range biological test results (including shift from baseline values) up to 28 days after injection | Number of participants with out-of-range biological test results | Up to 28 days after injection | |
| Secondary | Hemagglutination inhibition (HAI) antibody (Ab) titers to homologous H3 strain at D29, D91, and D181 | Antibody titers are expressed as Geometric Mean Titers (GMTs) | At Day 29, Day 91, and Day 181 | |
| Secondary | Individual HAI Ab titer ratio D29/D01, D91/D01, D91/D29, D181/D01, and D181/D29 | Ratios of antibody titers measured by HAI in each group before and after vaccination | From baseline up to 6 months | |
| Secondary | HAI Ab titer = 40 [1/dil] at D29, D91, and D181 | At Day 29, Day 91 and Day 181 | ||
| Secondary | 2-fold and 4-fold rise in HAI titers from D01 to D91 and D01 to D181 | From Day 01 through Day 91 and Day 01 through Day 181 | ||
| Secondary | Neutralizing Ab titers to homologous H3 strain at D29, D91, and D181 | At Day 29, Day 91, and Day 181 | ||
| Secondary | Individual neutralizing Ab titer ratio D29/D01, D91/D01, D91/D29, D181/D01, and D181/D29 | From baseline up to 6 months | ||
| Secondary | 2-fold and 4-fold rise in neutralizing titers from D01 to D91 and D01 to D181 | From Day 01 through Day 29 and Day 01 through Day 181 | ||
| Secondary | HAI Ab titers to selected heterologous H3 strains at D01, D29, D91, and D181 | At Day 01, Day 29, D91 and D181 | ||
| Secondary | Neutralizing Ab titers to selected heterologous H3 strains at D01, D29, D91, and D181 | At Day 01, Day 29, Day 91, and Day 181 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |